Phaseline

Companies › Tenax Therapeutics

Tenax Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Levosimendan (TNX-103)
Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator
PDE3A, PDE3B, TNNC1, TNNI3, TNNT2Phase 3Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic ShockJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04020263Levosimendan (TNX-103)Phase 3Cardiogenic ShockCardiovascularFeb 2027
NCT07105202Levosimendan (TNX-103)Phase 4Mechanical VentilationOtherAug 2027
NCT07288398Levosimendan (TNX-103)Phase 3Pulmonary Hypertension Associated With HFpEFCardiovascularJun 2028
NCT05983250Levosimendan (TNX-103)Phase 3Pulmonary HypertensionCardiovascularOct 2028

From the company's SEC filings

Cash of $114m on 2026-09-30; operating cash outflow about $48m a year; runway about 28 months at that burn, to Feb 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDE3A (1) PDE3B (1) TNNC1 (1) TNNI3 (1) TNNT2 (1)

Companies with the same targets

MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Merck & Co. (MSD)

Companies built like this

Braveheart Bio RHEACELL GmbH & Co. KG Mezzion Pharma Getz Pharma Tetra Discovery Partners

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.